# Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)

> **NCT02816970** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT02816970
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-02
- **Final completion:** 2014-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02816970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02816970, "Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02816970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*